REFERENCES
1. Ferreira CR, van Karnebeek CDM, Vockley J, Blau N. A proposed nosology of inborn errors of metabolism. Genet Med 2019;21:102-6.
2. Ferreira CR, Rahman S, Keller M, Zschocke J. ICIMD Advisory Group. An international classification of inherited metabolic disorders (ICIMD). J Inherit Metab Dis 2021;44:164-77.
3. Cani I, Pondrelli F, Licchetta L, et al. Epilepsy and inborn errors of metabolism in adults: the diagnostic odyssey of a young woman with medium-chain acyl-coenzyme A dehydrogenase deficiency. Epilepsia Open 2022;7:810-6.
4. la Marca G, Carling RS, Moat SJ, et al. Current state and innovations in Newborn Screening: continuing to do good and avoid harm. Int J Neonatal Screen 2023;9:15.
5. Bick D, Ahmed A, Deen D, et al. Newborn screening by genomic sequencing: opportunities and challenges. Int J Neonatal Screen 2022;8:40.
7. Jones SA, Cheillan D, Chakrapani A, et al. Application of a novel algorithm for expanding newborn screening for inherited metabolic disorders across Europe. Int J Neonatal Screen 2022;8:20.
8. Burlina A, Jones SA, Chakrapani A, et al. A new approach to objectively evaluate inherited metabolic diseases for inclusion on newborn screening programmes. Int J Neonatal Screen 2022;8:25.
9. Lee H, Deignan JL, Dorrani N, et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA 2014;312:1880-7.
10. Yubero D, Brandi N, Ormazabal A, et al. Working Group. Targeted next generation sequencing in patients with inborn errors of metabolism. PLoS One 2016;11:e0156359.
11. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338-43.
13. Therrell BL, Padilla CD, Loeber JG, et al. Current status of newborn screening worldwide: 2015. Semin Perinatol 2015;39:171-87.
14. Kelly N, Makarem DC, Wasserstein MP. Screening of newborns for disorders with high benefit-risk ratios should be mandatory. J Law Med Ethics 2016;44:231-40.
15. Liu N, Xiao J, Gijavanekar C, et al. Comparison of untargeted metabolomic profiling vs traditional metabolic screening to identify inborn errors of metabolism. JAMA Netw Open 2021;4:e2114155.
16. Gelb MH, Lukacs Z, Ranieri E, Schielen PCJI. Newborn screening for lysosomal storage disorders: methodologies for measurement of enzymatic activities in dried blood spots. Int J Neonatal Screen 2019;5:1.
17. Bonaventura E, Alberti L, Lucchi S, et al. XALD-NBS Study Group. Newborn screening for X-linked adrenoleukodystrophy in Italy: diagnostic algorithm and disease monitoring. Front Neurol 2022;13:1072256.
18. Loeber JG, Platis D, Zetterström RH, et al. Neonatal screening in Europe revisited: an ISNS perspective on the current state and developments Since 2010. Int J Neonatal Screen 2021;7:15.
19. Castiñeras DE, Couce ML, Marin JL, González-Lamuño D, Rocha H. Newborn screening for metabolic disorders in Spain and worldwide. An Pediatr 2019;91:128.e1-14.
20. Grupo de trabajo del Sistema de Información del Programa de Cribado Neonatal del SNS. Programa de cribado neonatal del sistema nacional de salud. Informe de Evaluación. Año 2019. Ministerio de Sanidad, 2021. Available from: https://cpage.mpr.gob.es/producto/programa-cribado-neonatal-del-sistema-nacional-de-salud/ [Last accessed on 23 Apr 2024].
21. Valcárcel-Nazco C, García-Pérez L, Linertová R, et al. Development of newborn screening policies in Spain 2003-2022: what do we actually need to reach an agreement? Rare Dis Orphan Drugs J 2023; 2:19.
22. Giżewska M, van Wegberg AMJ, Maillot F, Trefz F, van Spronsen FJ. Caring for Ukrainian refugee children with acute and chronic diseases. Lancet 2022;399:1689.
23. Scarpa M, Bonham JR, Dionisi-Vici C, et al. Newborn screening as a fully integrated system to stimulate equity in neonatal screening in Europe. Lancet Reg Health Eur 2022;13:100311.
24. Sikonja J, Groselj U, Scarpa M, et al. Towards achieving equity and innovation in newborn screening across Europe. Int J Neonatal Screen 2022;8:31.
25. Tayoun AN. Unequal global implementation of genomic newborn screening. Nat Rev Genet 2023;24:801-2.
26. McHugh D, Cameron CA, Abdenur JE, et al. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med 2011;13:230-54.
27. Siri B, Olivieri G, Angeloni A, et al. The diagnostic challenge of mild citrulline elevation at newborn screening. Mol Genet Metab 2022;135:327-32.
28. Auray-Blais C, Boutin M, Lavoie P, Maranda B. Neonatal urine screening program in the province of Quebec: technological upgrade from thin layer chromatography to tandem mass spectrometry. Int J Neonatal Screen 2021;7:18.
29. Dimmock D, Caylor S, Waldman B, et al. Project baby bear: rapid precision care incorporating rWGS in 5 California children’s hospitals demonstrates improved clinical outcomes and reduced costs of care. Am J Hum Genet 2021;108:1231-8.
30. Tangeraas T, Saeves I, Klingenberg C, et al. Performance of expanded newborn screening in Norway supported by post-analytical bioinformatics tools and rapid second-tier DNA analyses. Int J Neonatal Screen 2020;6:51.
31. Spiekerkoetter U, Bick D, Scott R, et al. Genomic newborn screening: are we entering a new era of screening? J Inherit Metab Dis 2023;46:778-95.
32. Bros-Facer V, Taylor S, Patch C. Next-generation sequencing-based newborn screening initiatives in Europe: an overview. Rare Dis Orphan Drugs J 2023;2:21.
33. Goldenberg AJ, Ponsaran R, Gaviglio A, Simancek D, Tarini BA. Genomics and newborn screening: perspectives of public health programs. Int J Neonatal Screen 2022;8:11.
34. White S, Mossfield T, Fleming J, et al. Expanding the Australian newborn blood spot screening program using genomic sequencing: do we want it and are we ready? Eur J Hum Genet 2023;31:703-11.
35. Smedley D, Smith KR, Martin A, et al. 100,000 genomes pilot on rare-disease diagnosis in health care - preliminary report. N Engl J Med 2021;385:1868-80.
36. Hoytema van Konijnenburg EMM, Wortmann SB, Koelewijn MJ, et al. Treatable inherited metabolic disorders causing intellectual disability: 2021 review and digital app. Orphanet J Rare Dis 2021;16:170.
37. Gold NB, Adelson SM, Shah N, et al. Perspectives of rare disease experts on newborn genome sequencing. JAMA Netw Open 2023;6:e2312231.
38. Huang X, Wu D, Zhu L, et al. Application of a next-generation sequencing (NGS) panel in newborn screening efficiently identifies inborn disorders of neonates. Orphanet J Rare Dis 2022;17:66.
39. Magnifico G, Artuso I, Benvenuti S. A systematic review of real-world applications of genome sequencing for newborn screening. Rare Dis Orphan Drugs J 2023;2:16.
40. Balciuniene J, Liu R, Bean L, et al. At-risk genomic findings for pediatric-onset disorders from genome sequencing vs medically actionable gene panel in proactive screening of newborns and children. JAMA Netw Open 2023;6:e2326445.
41. Bailey DB Jr, Porter KA, Andrews SM, Raspa M, Gwaltney AY, Peay HL. Expert evaluation of strategies to modernize Newborn Screening in the United States. JAMA Netw Open 2021;4:e2140998.
42. Millington DS, Bali DS. Current state of the art of newborn screening for lysosomal storage disorders. Int J Neonatal Screen 2018;4:24.
43. Kubaski F, Sousa I, Amorim T, et al. Pilot study of newborn screening for six lysosomal diseases in Brazil. Mol Genet Metab 2023;140:107654.
44. Tangeraas T, Constante JR, Backe PH, et al. BCKDK deficiency: a treatable neurodevelopmental disease amenable to newborn screening. Brain 2023;146:3003-13.
45. Plecko B. On pathways and blind alleys-the importance of biomarkers in vitamin B6 -dependent epilepsies. J Inherit Metab Dis 2023;46:839-47.
46. Abiusi E, Vaisfeld A, Fiori S, et al. Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis. J Med Genet 2023;60:697-705.
47. Genomics England. Conditions list. List of the genes and conditions that will be included when the Generation Study begins. Available from: https://www.genomicsengland.co.uk/initiatives/newborns/choosing-conditions/conditions-list-generation-study [Last accessed on 23 Apr 2024].
48. Liang NSY, Watts-Dickens A, Chitayat D, Babul-Hirji R, Chakraborty P, Hayeems RZ. Parental preferences for expanded newborn screening: what are the limits? Children 2023;10:1362.
49. Rehm HL, Alaimo JT, Aradhya S, et al. Medical Genome Initiative Steering Committee. The landscape of reported VUS in multi-gene panel and genomic testing: time for a change. Genet Med 2023;25:100947.
